HomeDrug ClassesDDCI / COMT Inhibitor Combinations

DDCI / COMT Inhibitor Combinations: Uses, Common Brands, and Safety Info

DDCI/COMT inhibitor combinations are drug classes used to treat Parkinson's disease, increasing dopamine levels. Common brands include Stalevo, Duodopa, and Comtan. While generally safe, they may cause side effects such as nausea and dizziness. Patients should inform their healthcare provider about pre-existing conditions and medications. Overall, these combinations can improve motor control in Parkinson's disease.


DDCI/COMT inhibitor combinations are a class of drugs used in the treatment of Parkinson's disease. These combinations consist of a peripheral DDCI (dopa decarboxylase inhibitor) and a COMT inhibitor (catechol-O-methyltransferase inhibitor). The combined action of these drugs helps to increase the levels of dopamine in the brain, which can alleviate the symptoms of Parkinson's disease.


DDCI/COMT inhibitor combinations are primarily prescribed for patients with Parkinson's disease who experience motor fluctuations. These drugs can reduce "off" periods, which are characterized by a return of Parkinson's symptoms such as tremors, rigidity, and bradykinesia. By extending the effectiveness of levodopa, a commonly used medication for Parkinson's disease, DDCI/COMT inhibitor combinations can help improve motor control and overall quality of life for patients.

Common Brands

Some common brands of DDCI/COMT inhibitor combinations include: - Stalevo (carbidopa/levodopa/entacapone) - Duodopa (levodopa/carbidopa intestinal gel) - Comtan (entacapone) It is important to note that the availability of specific brands may vary depending on the country and healthcare system.


DDCI/COMT inhibitor combinations are generally safe and well-tolerated when used as prescribed by a healthcare professional. However, like any medication, they can have potential side effects. Common side effects associated with DDCI/COMT inhibitor combinations may include nausea, diarrhea, dizziness, orthostatic hypotension (low blood pressure), and dyskinesias (involuntary movements). It is essential for patients to discuss any bothersome side effects with their healthcare provider. As with all medications, DDCI/COMT inhibitor combinations should be used with caution in certain populations. Individuals with a history of liver disease or those taking certain other medications may require dosage adjustments or closer monitoring. It is crucial to inform the healthcare provider about any pre-existing medical conditions or medications being taken to ensure the safe and effective use of DDCI/COMT inhibitor combinations. In conclusion, DDCI/COMT inhibitor combinations are a class of drugs commonly used in the management of Parkinson's disease. By enhancing the availability of dopamine in the brain, these combinations can help reduce motor fluctuations and improve overall motor control. As with any medication, patients should follow their healthcare provider's instructions and report any concerns or side effects promptly.